27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Panbela Therapeutics Inc (NASDAQ:PBLA) shares are trading higher by 9.7% to $0.50, though off the session high of $0.64. The move comes after the company announced FDA approval of eflornithine, a drug they divested to US WorldMeds, for treating high-risk neuroblastoma patients who responded partially to prior therapies.
Panbela Therapeutics says this marks the first FDA approval for a polyamine targeted therapy in cancer. Panbela stands to receive up to $9.5 million based on milestones achieved by USWM, emphasizing the significance of polyamines in cancer therapy.
Panbela's executives expressed excitement over the approval, highlighting its potential impact on neuroblastoma treatment and the broader implications for other cancers being explored.
See Also: Why Fresh Tracks Therapeutics (FRTX) Shares Are Volatile
According to data from Benzinga Pro, PBLA has a 52-week high of $225.71 and a 52-week low of $0.45.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!